Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

By V. Viswanathan, M. Ryan, Harshil Dhruv, S. Gill, Ossia M. Eichhoff, Brinton Seashore-Ludlow, S. Kaffenberger, J. Eaton, K. Shimada, A. Aguirre and 30 more. Nature, 2017

1,715 citations recorded by the source corpus.

Plasticity of the cell state has been proposed to drive resistance to multiple classes of cancer therapies, thereby limiting their effectiveness. A high-mesenchymal cell state observed in human tumours and cancer cell lines has been associated with resistance to multiple treatment modalities across diverse cancer lineages, but the mechanistic underpinning for this state has remained incompletely understood. Here we molecularly characterize this therapy-resistant high-mesenchymal cell state in human cancer cell lines and organoids and show that it depends on a druggable lipid-peroxidase pathway that protects against ferroptosis, a non-apoptotic form of cell death induced by the build-up of toxic lipid peroxides. We show that this cell state is characterized by activity of enzymes that promote the synthesis of polyunsaturated lipids. These lipids are the substrates for lipid peroxidation by lipoxygenase enzymes. This lipid metabolism creates a dependency on pathways converging on the phospholipid glutathione peroxidase (GPX4), a selenocysteine-containing enzyme that dissipates lipid peroxides and thereby prevents the iron-mediated reactions of peroxides that induce ferroptotic cell death. Dependency on GPX4 was found to exist across diverse therapy-resistant states characterized by high expression of ZEB1, including epithelial–mesenchymal transition in epithelial-derived carcinomas, TGFβ-mediated therapy-resistance in melanoma, treatment-induced neuroendocrine transdifferentiation in prostate cancer, and sarcomas, which are fixed in a mesenchymal state owing to their cells of origin. We identify vulnerability to ferroptic cell death induced by inhibition of a lipid peroxidase pathway as a feature of therapy-resistant cancer cells across diverse mesenchymal cell-state contexts.

Subfields: Cancer Research, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/1a416c89a5af417c3c3a3cecd53e6ea160789cfa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Pulmonary and Respiratory Medicine

In Surgery

Citations in the corpus

Dynamic EMT: a multi‐tool for tumor progression (2021, positive): “Initial TGF b receptor activation in breast or skin cancer results in transcriptional activation of SNAI 1 , combined with sumoylation of SNAIL at K 234 fostering SMAD/SNAIL complex formation that promotes EMT (Hoot et al , 2008 ; Vincent et al , 2009 ; Gudey et al , 2017 ) (Fig 4 B).”
The interaction between ferroptosis and lipid metabolism in cancer (2020, background): “Some chemotherapies are sensitive to ferroptosis induced by GPX4 inhibition.(83,84) Moreover, as a key regulator of lipid metabolism, ACSL4 also produces LPO during the process of ferroptosis.”
Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. (2022, positive): “Aggressive cancers that have undergone epithelial-to-mesenchymal transition are more susceptible to ferroptosis (Viswanathan et al., 2017), and resistance to targeted agents that induce apoptosis is associated with increased sensitivity to ferroptosis (Hangauer et al.”
Role of Mitochondria in Ferroptosis (2018, background): “, 2016); and many types of cancer cells that are resistant to chemotherapy and certain targeted therapies appear to be sensitive to ferroptosis induced by GPX4 inhibition (Hangauer et al., 2017; Viswanathan et al., 2017).”
Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies (2024, background): “247 (Fig.”
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance (2022, background): “found that the therapy-resistant high-mesenchymal cell state depends on the GPX4-regulated lipid-peroxidase pathway that protects against ferroptosis [12].”
Ferroptosis: mechanisms and links with diseases (2021, background): “ZEB1, which promotes tumor invasion and therapyresistant by inducing EMT in carcinoma cells, was found to regulate the sensitivity of mesenchymal state cancer cells to GPx4 inhibition as a lipogenic factor.(111) In a recent study, the loss of tumor suppressor Merlin, a frequent tumourigenic event in”